Randomized trials of systemic medically-treated malignant mesothelioma: A systematic review

Anticancer Research

Volumn 35, Issue 5, 2015, Pages 2493-2502

  Blomberg, Carl ^a,c,d   Nilsson, Jonas ^a,c,d   Holgersson, Georg ^a,b,c   Edlund, Per ^a   Bergqvist, Michael ^a,c,d   Adwall, Linda ^b   Ekman, Simon ^b   Brattström, Daniel ^b   Bergström, Stefan ^a,b,d  

^a GÄVLE HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Malignant mesothelioma; Randomized trials; Review

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; MITOMYCIN; NAVELBINE; PEMETREXED; THALIDOMIDE; VINBLASTINE; VORINOSTAT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; HUMAN; KARNOFSKY PERFORMANCE STATUS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC THERAPY; TIME TO TREATMENT; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; MESOTHELIOMA; MULTIMODALITY CANCER THERAPY; PALLIATIVE THERAPY; PATHOLOGY; PLEURAL NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; PALLIATIVE CARE; PLEURAL NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84929692733     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Ong ST and Vogelzang NJ: Chemotherapy in malignant pleural mesothelioma. A review. J Clin Oncol 14: 1007-17. 1996.
2. Hillerdal G: Malignant mesothelioma 1982: review of 4710 published cases. Br J Dis Chest 77(4): 321-43, 1983.
3. Sorensen PG, Bach F, Bork E and Hansen HH: Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep 69: 1431-1432, 1985.
4. Cantwell BM, Franks CR and Harris AL: A phase II study of the platinum analogues JM8 and JM9 in malignant pleural mesothelioma. Cancer Chemother Pharmacol 18: 286-288, 1986.
5. Samson MK, Wasser LP, Borden EC, Wanebo HJ, Creech RH, Phillips M and Baker LH: Randomized comparison of cyclophosphamide, imidazole carboxamide, and Adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study. J Clin Oncol 5: 86-91. 1987.
6. Chahinian AP, Antman K, Goutsou M, Corson JM, Suzuki Y, Modeas C, Herndon JE 2nd, Aisner J, Ellison RR and Leone L: Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 11: 1559-1565. 1993.
7. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C and Paoletti P: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644. 2003.
8. Boyer MJ, Jassem J and Liepa AM: Symptom and quality of life advantages for pemetrexed+cisplatin versus cisplatin in treatment of malignant pleural mesothelioma (abstract). Lung Cancer 41: S19, (suppl 2) 2003.
9. Vogelzang NJ, Rusthoven J and Paoletti P: Phase III single-blinded study of pemetrexed+cisplatin vs. cisplatin alone in chemonaive patients with malignant pleural mesothelioma (abstract). Proc Am Soc Clin Oncol 21: A5, 2002.
10. van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C and Giaccone G: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23: 6881-6889, 2005.
11. Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, Nicholson AG, O'Brien M, Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C and Parmar MK: Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 371: 1685-94, 2008.
12. Kindler HL, Karrison TG, Gandara DR Lu C, Krug LM, Stevenson JP, Jänne PA, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG 3rd, Vogelzang NJ, Chen HX, Stadler WM and Vokes EE: Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.J Clin Oncol 30: 2509-15, 2012.
13. Habib EE and Fahmy ES: Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimes. Clin Transl Oncol 15: 965-968, 2013.
14. Krug LM, Wozniak AJ, Kindler HL Feld R, Koczywas M, Morero JL, Rodriguez CP, Ross HJ, Bauman JE, Orlov SV, Ruckdeschel JC, Mita AC, Fein L, He X, Hall R, Kawabe T and Sharma S: Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.Lung Cancer 85: 429-34, 2014.
15. Millenson MM, Lee J, Hanna NH, Langer J, Hoang T, Graham DL, Okuno SH and Schilleret JH: Pemetrexed plus gemcitabine or carboplatin in patients with advanced malignant mesothelioma: A randomized phase II trial (abstract). J Clin Oncol 28: (suppl; abstr e18053), 2010.
16. Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer JF, Lind MJ, Bomalaski JS, Fennell DA and Hackshawet A: Randomized trial of arginine deprivation with pegylated arginine deiminase in patients with malignant pleural mesothelioma. J Clin Oncol 32: 5s (suppl; abstr 7507), 2014.
17. Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A and Manegold C: Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 26: 1698-704, 2008.
18. Buikhuisen WA, Burgers JA, Vincent AD Korse CM, van Klaveren RJ, Schramel FM, Pavlakis N, Nowak AK, Custers FL, Schouwink JH, Gans SJ, Groen HJ, Strankinga WF and Baas P: Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. Lancet Oncol 14: 543-51, 2013.
19. Reck M, Krzakowski M, Jassem J, Eschbach C, Kozielski J, Costanzi JJ, Gatzemeier U, Shogen K and von Pawel J: Randomized, multicenter phase III study of ranpirnase plus doxorubicin versus doxorubicin in patients with unresectable malignant mesothelioma J Clin Oncol 27: 15s (suppl; abstr 7507), 2009.
20. Krug LM, Kindler H, Calvert H, Manegold C, Tsao AS, Fennell D, Lubiniecki GM, Sun X, Smith M and Baas P: Vorinostat in patients with advanced malignant pleural mesothelioma who have failed prior pemetrexed and either cisplatin or carboplatin therapy: A phase III, randomized, double-blind, placebo-controlled trial Eur J Cancer 47: 2-3, 2011.
21. Sterman DH and Albelda SM. Advances in the diagnosis, Evaluation and Management of Malignant Pleural Mesothelioma. Respirology 10: 266-283, 2005.
22. Ahamad A, Stevens CW, Smythe WR, Liao Z, Vaporciyan AA, Rice D, Walsh G, Guerrero T, Chang J, Bell B, Komaki R and Forster KM: Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. Cancer J 9: 476-84. 2003.
23. Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, Flores R, Friedberg JS, Pisters K, Monberg M, Obasaju CK and Vogelzang NJ: Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 27: 3007-13. 2009.
24. Craighead JE: Epidemiology of mesothelioma and historical background. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 189: 13-25, 2011.
25. Robinson BW, Musk AW and Lake RA. Malignant mesothelioma. Lancet 366: 397-408, 2005.
26. Delgermaa V, Takahashi K, Park EK, Le GV, Hara T and Sorahan T: Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bulletin of the World Health Organization 89: 716-724, 724A-724C, 2011.
27. Peto J, Hodgson JT, Matthews FE and Jones JR: Continuing increase in mesothelioma mortality in Britain. Lancet 345: 535-9, 1995.
28. Peto J, Decarli A, La Vecchia C, Levi F and Negri E: The European mesothelioma epidemic. Br J Cancer 79: 666-72, 1999.
29. Murayama T, Takahashi K, Natori Y and Kurumatani N: Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model. Am J Ind Med 49: 1-7, 2006.
30. Montanaro F, Bray F, Gennaro V, Merler E, Tyczynski JE, Parkin DM, Strnad M, Jechov'a M, Storm HH, Aareleid T, Hakulinen T, Velten M, Lef'evre H, Danzon A, Buemi A, Daur'es JP, Ménégoz F, Raverdy N, Sauvage M, Ziegler H, Comber H, Paci E, Vercelli M, De Lisi V, Tumino R, Zanetti R, Berrino F, Stanta G, Langmark F, Rachtan J, Mezyk R, Blaszczyk J, Ivan P, Primic-Zakelj M, Martínez AC, Izarzugaza I, Borràs J, Garcia CM, Garau I, Sánchez NC, Aicua A, Barlow L, Torhorst J, Bouchardy C, Levi F, Fisch T, Probst N, Visser O, Quinn M, Gavin A, Brewster D and Mikov M: Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends. Cancer Causes Control 14: 791-803, 2003.
31. Tse LA, Yu IT, Goggins W, Clements M, Wang XR, Au JS, Yu KS: Are current or future mesothelioma epidemics in Hong Kong the tragic legacy of uncontrolled use of asbestos in the past? Environ Health Perspect 118: 382-6, 2010.
32. Vogelzang NJ: Chemotherapy for malignant pleural mesothelioma. Lancet 371: 1640-2, 2008.
33. Francart J, Legrand C, Sylvester R, Van Glabbeke M, van Meerbeeck JP and Robert A: Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma - The EORTC Lung Cancer Group. J Clin Oncol 24: 3007-12, 2006.
34. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-16, 2000.
35. Byrne MJ and Nowak AK: Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15: 257-60, 2004.
36. Nowak AK: CT, RECIST, and malignant pleural mesothelioma. Lung Cancer 49, Suppl 1:S37, 2005.
37. Berghmans T, Paesmans M, Lalami Y Louviaux I, Luce S, Mascaux C, Meert AP and Sculier JP: Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of literature with meta-analysis. Lung Cancer 38: 111-121, 2002.
38. Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Parra HJ and Santoro A: Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 24: 1443-8, 2006.
39. Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, Serra M, Muzio A, Carbone R, Buosi R, Galbusera V, Piccolini E, Giaretto L, Rebella L and Mencoboni M: Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma. Ann Oncol 19: 370-3, 2008.
40. Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM and Manegold C: Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 3: 756-63, 2008.
41. Ceresoli GL, Castagneto B, Zucali PA, Favaretto A, Mencoboni M, Grossi F, Cortinovis D, Del Conte G, Ceribelli A, Bearz A, Salamina S, De Vincenzo F, Cappuzzo F, Marangolo M, Torri V and Santoro A: Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. Br J Cancer 99: 51-6, 2008.
42. Zucali PA, Ceresoli GL, Garassino I, De Vincenzo F, Cavina R, Campagnoli E, Cappuzzo F, Salamina S, Soto Parra HJ and Santoro A: Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer 112: 1555-61, 2008.
43. Xanthopoulos A, Bauer TT, Blum TG, Kollmeier J, Schonfeld N and Serke M: Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study. J Occup Med Toxicol 3: 34-40, 2008.
44. Stebbing J, Powles T, McPherson K, Shamash J, Wells P, Sheaff MT, Slater S, Rudd RM, Fennell D and Steele JP: The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 63: 94-97, 2009.
45. Pasello G, Nicotra S, Marulli G, Rea F, Bonanno L, Carli P, Magro C, Jirillo A and Favaretto A: Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: A mono-institutional experience. Lung Cancer 37: 351-5, 2011.
46. Ceresoli GL, Zucali PA, De Vincenzo F, Gianoncelli L, Simonelli M, Lorenzi E, Ripa C, Giordano L and Santoro A: Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer 72: 73-77, 2011.